

I hereby certify that this correspondence is being electronically filed in the United States Patent and Trademark Office on October 1, 2010.

Patent Application  
Docket No. GJE.7664  
Serial No. 10/586,080

Doran R. Pacc, Patent Attorney

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Examiner : Joanne Hama  
Art Unit : 1632  
Applicants : Mervi Ahlroth, Diana Schenkwein, Kari Juhani Airenne,  
Seppo Yla-Herttuala, Olli Laitinen  
Serial No. : 10/586,080  
Filed : September 24, 2008  
Confirm. No. : 9433  
For : Integrase Fusion Proteins and Their Use with Integrating Gene Therapy

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

**SUBMISSION OF SEQUENCE LISTING AND  
STATEMENT UNDER 37 CFR §§1.821-1.825**

Sir:

Transmitted herewith is a Sequence Listing under 37 CFR §§1.821 through 1.825 for the above-identified patent application. The July 1, 2010 Office Action was received from the Patent and Trademark Office with a Notice to Comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures.

The Sequence Listing is submitted in computer readable format and on paper. I hereby certify that the paper and computer readable copies contain the same information and that no new material is added by this submission.

The Commissioner is hereby authorized to charge any fees under 37 CFR §§ 1.16 or 1.17 as required by this paper to Deposit Account No. 19-0065.

Respectfully submitted,



Doran R. Pace  
Patent Attorney  
Registration No. 38,261  
Phone No.: 352-375-8100  
Fax No.: 352-372-5800  
Address: Saliwanchik, Lloyd & Saliwanchik  
A Professional Association  
P.O. Box 142950  
Gainesville, FL 32614-2950

DRP/mv

Attachments: Sequence Listing on paper and computer readable format